Table 3.
CMR findings in RA patients based on anti-TNF use
| Anti-TNF users (N=29) |
Anti-TNF non- users (N=30) |
P | Adjusted P | |
|---|---|---|---|---|
| Heart rate, bpm | 71 [66, 76] | 73 [65, 79] | 0.83 | 0.94 |
| LV mass indexed to BSA, g/m2 | 42.9 [39.3, 49.5] | 44.5 [41.6, 50.0] | 0.09 | 0.33 |
| LVEF, % | 69.2 [64.0, 75.9] | 67.1 [62.3, 74.7] | 0.52 | 0.70 |
| LVEDV indexed to BSA, ml/m2 | 59.3 [52.5, 64.5] | 58.9 [44.4, 69.7] | 0.85 | 0.53 |
| LVESV indexed to BSA, ml/m2 | 17.7 [12.8, 23.7] | 19.2 [10.8, 24.7] | 0.78 | 0.93 |
| LV ci, l/min/m2 | 2.84 [2.66, 3.17] | 2.65 [2.20, 3.03] | 0.35 | 0.14 |
| LA size, mm | 29 [25, 33] | 29 [24, 31] | 0.08 | 0.15 |
| RVEF, % | 62.1 [57.5, 68.2] | 61.4 [56.4, 66.2] | 0.35 | 0.33 |
| RVEDV indexed to BSA, ml/m2 | 58.9 [52.2, 68.7] | 56.6 [46.3, 72.6] | 0.74 | 0.89 |
| RVESV indexed to BSA, ml/m2 | 20.4 [15.8, 27.4] | 20.5 [15.7, 31.4] | 0.78 | 0.61 |
| RA size, mm | 30 [27, 35] | 29 [24, 35] | 0.31 | 0.21 |
| Presence of LGE, # (%) | 1 (3.4) | 1 (3.3) | - | - |
| Native myocardial T1, msec | 946 [919, 995] | 979 [948, 996] | 0.19 | 0.10 |
| Post-contrast T1, msec | 447 [425, 469] | 459 [436, 479] | 0.24 | 0.83 |
| ECV, % | 25.6 [24.3, 28.4] | 27.1 [25.0, 28.6] | 0.21 | 0.13 |
Adjusted for age, race and sex. BPM= beats per minute, LV= left ventricular, BSA= body surface area, EF= ejection fraction, EDV= end diastolic volume, ESV= end systolic volume, ci= cardiac index, LA= left atrium, RV= right ventricle, RA=right atrium, LGE= late gadolinium enhancement, ECV=extracellular volume.